A Phase IB/II Study of Sunitinib in Combination With Neoadjuvant Radiation in Patients With Resectable Soft-Tissue Sarcoma.

Trial Profile

A Phase IB/II Study of Sunitinib in Combination With Neoadjuvant Radiation in Patients With Resectable Soft-Tissue Sarcoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Soft tissue sarcoma
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Oct 2014 Status changed from active, no longer recruiting to completed according to results published in the British Journal of Cancer.
    • 01 Jan 2013 Status changed from recruiting to active, no longer recruiting according to results published in the British Journal of Cancer.
    • 08 May 2009 Additional trial identifiers (ACTRN12608000474358, 083144, 08/05) identified as reported by Australian New Zealand Clinical Trials Registry record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top